Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ropinirole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 15/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.97 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 0.97 |
| ▸ | DRD5 | P21918 | 2/20 | 0.97 |
| ▸ | HTR1A | P08908 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ropinirole SCHEMBL40760 | 1.00 | APEX1 (1.00) | APEX1BLMDRD2DRD1DRD4 | |
| Ropinirole SCHEMBL4623647 | 1.00 | APEX1 (1.00) | APEX1BLMDRD2DRD1DRD4 | |
| Ropinirole SCHEMBL1787068 | 1.00 | APEX1 (1.00) | APEX1BLMDRD2DRD1DRD4 | |
| Ropinirole SCHEMBL35212 | 0.99 | DRD2 (1.00) | APEX1BLMDRD2DRD1DRD4 | |
| Ropinirole SCHEMBL29374522 | 0.99 | DRD2 (1.00) | APEX1BLMDRD2DRD1DRD4 | |
| Ropinirole SCHEMBL29278850 | 0.97 | DRD2 (0.97) | APEX1BLMDRD2DRD1DRD4 | |
| Ropinirole SCHEMBL16044076 | 0.97 | DRD2 (0.97) | APEX1BLMDRD2DRD1DRD4 | |
| Ropinirole SCHEMBL28866728 | 0.96 | APEX1 (0.93) | APEX1BLMDRD2DRD1DRD4 | |
| Ropinirole SCHEMBL678982 | 0.96 | DRD2 (0.95) | APEX1BLMDRD2DRD1DRD4 | |
| Ropinirole SCHEMBL28937023 | 0.96 | DRD2 (0.95) | APEX1BLMDRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230381195-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI) AND RELATED DISORDERS | MEHRA AKHIL (US) | 2023-11-30 | — | — | US | claimed |
| WO-2023172561-A1 | USE OF BLINK REFLEX FOR PARKINSON'S DISEASE RESPONSE MONITORING AND/OR TREATMENT SELECTION | Blinktbi, Inc. (US) | 2023-09-14 | — | — | WO | claimed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| EP-4687886-A1 | METHODS OF DOSING SPINOGENIC COMPOUNDS | Spinogenix, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| US-20250375396-A1 | SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG | CORIUM LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250325496-A1 | SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG | CORIUM LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12427179-B2 | Compositions and methods for diagnosis and treatment of neurodegenerative diseases | Epitracker, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4017524-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | Standard of Care Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11351169-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022112511-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INNER EAR DISORDERS THROUGH LOCAL ADMINISTRATION IN THE TYMPANIC AREA | MOUSSY ALAIN (FR) | 2022-06-02 | — | — | WO | disclosed |
| US-20220160639-A1 | MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | NLS PHARMACEUTICS AG (CH) | 2022-05-26 | — | — | US | disclosed |
| US-20220096451-A1 | POLYVALENT DERIVATIVES OF EMOXYPINE | RIESNER VERWALTUNGS GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| WO-2022056475-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A DYSTONIA | DUKE UNIVERSITY (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3966199-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2022-03-16 | — | — | EP | disclosed |
| US-11234961-B2 | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof | GU ZI QIANG (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, GAA | DRD2 2947/4885DRD4 3115/4885DRD3 2023/4885 |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | DRD2 3637/4885DRD4 3331/4885DRD3 3174/4885 |
| US-20250375396-A1 | SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG | SLC10A2, SLC10A1, ABCB11 | DRD2 1942/4885DRD4 1971/4885DRD3 1716/4885 |
| US-20220096451-A1 | POLYVALENT DERIVATIVES OF EMOXYPINE | PARK7, SNCA, COMT | DRD2 110/4885DRD4 97/4885DRD3 169/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | DRD2 3587/4885DRD4 3650/4885DRD3 3019/4885 |
| US-11351169-B2 | Methods of treating dyskinesia and related disorders | SLC6A3, CHAT, ACHE | DRD2 900/4885DRD4 1052/4885DRD3 1344/4885 |
| US-20250325496-A1 | SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG | SLC10A2, SLC10A1, ABCB11 | DRD2 1942/4885DRD4 1971/4885DRD3 1716/4885 |
| US-20220160639-A1 | MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | DRD2, DRD3, DRD1 | DRD2 1/4885DRD4 4/4885DRD3 2/4885 |
| US-11234961-B2 | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof | PAM, SNCA, MTNR1A | DRD2 208/4885DRD4 163/4885DRD3 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.